The Investigational Study

Currently Recruiting

16 Nov 2025 to 8 Jan 2026

Up to $8,210

The Study Drug is being developed as a once-daily oral medication that targets a specific receptor in the body to help manage carcinoid syndrome 

The purpose of this study is to assess different dosing regimens and formulations to determine if they are comparable in terms of safety, tolerability, and how the drug behaves in the body. This is important because current treatments don’t work well for everyone and can be difficult to use or cause unwanted side effects. 

Ultimately, the aim is to find a treatment that’s easier to take, more effective, and safer—helping people with carcinoid syndrome live healthier, more comfortable lives. 

Apply now Speak with us

Join our clinical trial

This is not a first-in-human (FIH) study, meaning it is not the first time the potential treatment is being tested in people. The study has been carefully designed with strict safety protocols and has been approved by an independent ethics committee. 

Before joining, you’ll receive detailed information about the study, meet with a doctor, and have the chance to ask any questions. 

This is an early-stage  study, we’re looking to understand: 

  • How well the potential treatment is tolerated 
  • How the body processes the potential treatment and its byproducts. 
Nucleus Network - Image

Trial details

Study medication

Administered as either one or two tablets depending on which treatment sequence you are in.

Ethics

An independent ethics committee has approved this clinical trial. 

Additional eligibility

  • Non-smokers or smoking no more than 5 cigarettes per week, no tobacco or nicotine use during your stay 
  • No caffeine or caffeine containing beverages (e.g., coffee, tea, caffeinated soda, energy drinks, chocolate)
  • Prescription medications must be complete 14 days prior to admission (as discussed with our medical team) 
  • Be able to refrain from strenuous exercise 3 days prior to screening 
  • Not pregnant or breastfeeding 
  • Willing to follow contraception guidelines (if applicable) 
  • Able to attend all study visits and follow instructions 

Study duration

3 x 4-night in-clinic stays (total of 12 nights), 7 follow-up visits and 1 phone call

Are you a match?

Age

18 - 55 years old

Remuneration

Up to $8,210 *with screening reimbursement. Please see T&Cs.

Gender

Male or Female

BMI

BMI 18 - 30 kg/m2

Commitment

12 nights, 7 clinic visits

Medical condition

Not taking any medications

Register Your Interest

This form takes around 3–5 minutes to complete. Your information will remain confidential and is used only to assess your eligibility for current or future research studies.
Step 1 of 3
Contact Information




The phone number you have entered does not appear to be a valid active Australian phone number. Please check your details and enter a valid Australian phone number starting with +61

Nucleus Network does not currently conduct clinical trials in your state. If you would like to receive study information should this situation change, please complete and submit this form.
Personal Information

This includes registering your interest with the Centre for Clinical Studies, Q-Pharm or Nucleus Network

Please call us on 1800 243 733 or schedule a call.


What is your date of birth?
Day Month Year

You need to be at least 18 years old to participate in clinical trials.


cm

kg





















Step 2 of 3
Medical History

We regularly have studies that allow participants who are (social) smokers.

We define an allergy as severe if symptoms include mouth/throat/face swelling, shortness of breath or a whole-body rash, or if it required hospitalisation

We regularly have studies that allow for/require participants with asthma.



We regularly have studies that allow for/require participants with medical conditions.

Medications & Contraception Requirements

We regularly have studies that allow participants with depression that is well-managed on a stable dose of medication.

If the only prescription medication you currently use is hormonal contraception and/or Ventolin, please select No above. We regularly have studies that allow for participants who take a stable dose of prescription medication.


  • Abstinence from sex with anyone of the opposite sex for at least 2 months
  • Using a condom + your female sexual partner(s) using a separate form of birth control
  • You or your sexual partner(s) had a vasectomy/hysterectomy
  • Your sexual partner(s) are post-menopausal


Only you taking birth control or your partner(s) using a condom is not an acceptable option, but using both together is. The morning after pill is not an acceptable form of birth control.

  • Abstinence, by choice, from sex with anyone of the opposite sex for the last 2 months + remaining abstinent for at least 2 months after study participation
  • You using birth control + your male sexual partner(s) using a condom
  • You or your sexual partner(s) had a hysterectomy/vasectomy
  • You are post-menopausal



Step 3 of 3
Study Preferences

While longer studies generally have a higher reimbursement, there are also studies with multiple short stays that have high reimbursements.
Referral Information



Consent to Information Use and Future Contact